REGULATORY COMPLIANCE

Real-time oversight

MAKING SURE THAT ALL MEDICINES ARE AVAILABLE TO PATIENTS WHO NEED THEM

In 2014, Ikris Pharma Network started a dedicated business focused on providing fully managed and regulatory compliant access for physicians and their patients to medicines that are not approved or available in India. We have expanded this service to offer the same access opportunities to physicians in other Asian countries as well. We ensure that genuine products can be accessed wherever a patient’s unmet clinical need requires it.
We also provide a regulatory compliant and cost effective solution for pharmaceutical companies to make medicines available to patients where their products are not registered for the marketing. This may happen when a medicine is new and has not yet been licensed for marketing in patient’s country or because a previously licensed medicine has been discontinued. In all these cases, IPN can provide patients with quick and secure access to the medicines they need.

PHARMACEUTICAL COMPANY’S ROAD TO ACCESS AND SATISFY PATIENT DEMAND.

Many companies having products, particularly niche-segment or start up pharmaceuticals companies are not able to reach to Asian countries market due to lack of resources and local market expertise. This is more relevant for the companies having products for rare diseases. Patients are thus deprived of access to new life saving medicines, which are simply not available in their country.

IPN offer their service to facilitate market access in such countries, through named patient distribution across India and other emerging markets in the region. Although it may look straightforward issues, importation process for un-registered medicines varies distinctly from country to country. With IPN having detailed knowledge of the relevant procedures and regulations saves both cost and time to market.

We can also help companies to license their product into a territory, when they feel that time is right. IPN are well placed to help pharmaceutical and biopharmaceutical companies license their niche products in India, should the demand be significant enough.